<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328834</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU-PRGLN-003</org_study_id>
    <nct_id>NCT01328834</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a pilot study to evaluate the efficacy and safety of Tacrolimus Sustained-release&#xD;
      Capsules (ADVAGRAF) treatment for the induction therapy of refractory lupus nephritis (LN).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate (complete or partial remission)</measure>
    <time_frame>6 months after therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of proteinuria</measure>
    <time_frame>every 3 months up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SLEDAI scores</measure>
    <time_frame>every 3 months up to 6 months</time_frame>
    <description>SLEDAI:Systemic Lupus Erythematosus Disease Activity Index (Bombardier et al, 1992).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>every 3 months up to 6 months</time_frame>
    <description>Adverse events, including infections, transient increases in serum creatinine, gastrointestinal complaints, liver function disorder and glucose intolerance, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of renal function</measure>
    <time_frame>every 3 months up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>every 3 months up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nephritis, Lupus</condition>
  <arm_group>
    <arm_group_label>ADVAGRAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Sustained-release Capsules (ADVAGRAF)</intervention_name>
    <description>Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.</description>
    <arm_group_label>ADVAGRAF</arm_group_label>
    <other_name>ADVAGRAF: Tacrolimus Sustained-release Capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects of either sex, 14-65 years of age;&#xD;
&#xD;
          2. Diagnosis of SLE according to the ACR criteria (1997);&#xD;
&#xD;
          3. Kidney biopsy within the 6 months prior to study with a histologic diagnosis (ISN/RPS&#xD;
             2003 classification of LN) class IV, V, V+ III, V+ IV;&#xD;
&#xD;
          4. Usage of intravenous pulse cyclophosphamide for more than 3 times or immunosuppression&#xD;
             therapy (AZA, MMF, oral cyclophosphamide, ect) for more than 6 months;&#xD;
&#xD;
          5. proteinuria &gt; 1g/24hr or Scr &gt; 1.3 mg/dl or active urinary sediment (erythrocyte cast,&#xD;
             &gt; 5 WBC/high power field (hpf) (excluding infection), &gt; 5 RBC/hpf);&#xD;
&#xD;
          6. Provision of written informed consent by subject or guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability or unwillingness to provide written informed consent ;&#xD;
&#xD;
          2. Usage of immunosuppression therapy (MMF, CTX, CysA, MTX etc) for more than 1 week&#xD;
             within 1 month or intravenous MP Pulse treatment prior to entry;&#xD;
&#xD;
          3. Scr &gt; 4mg/dl (354umol/L);&#xD;
&#xD;
          4. Needing pulse intravenous MP or intravenous immunoglobulin;&#xD;
&#xD;
          5. Lupus encephalopathy;&#xD;
&#xD;
          6. Diagnosed DM; Malignant tumors (except fully cured basal cell carcinoma);&#xD;
&#xD;
          7. History of significant gastrointestinal disorders (e.g. active peptic ulcer disease or&#xD;
             pancreatitis) within 3 month prior to enter this study;&#xD;
&#xD;
          8. Known hypersensitivity or contraindication to tacrolimus, corticosteroids&#xD;
&#xD;
          9. Any Active systemic infection or history of serious infection within one month of&#xD;
             entry or known infection with HIV, hepatitis B, or hepatitis C;&#xD;
&#xD;
         10. Participation in another clinic trial and/or receipt of investigational drugs within 4&#xD;
             weeks prior to screening;&#xD;
&#xD;
         11. Pregnancy, nursing or use of a non-reliable method of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Xueqing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, 1st Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University IRB</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2011</study_first_posted>
  <last_update_submitted>November 1, 2011</last_update_submitted>
  <last_update_submitted_qc>November 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Xueqing Yu</name_title>
    <organization>Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>Nephritis, Lupus</keyword>
  <keyword>Tacrolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

